Nitrogen-containing bisphosphonates (N-BPs) are therapeutic agents used to treat osteoporosis and promote osteoblast and osteocyte survival. The molecular mechanisms underlying this effect have been extensively studied, but the global changes induced by N-BPs at the protein level are not known. In this context, we investigated the effect of 10(-7)M Risedronate for 1h and 48h on MLO-Y4 osteocytic cells, through a quantitative, label free shotgun proteomic analysis. We described herein a preliminary proteome map of untreated MLO-Y4 cells, composed of 353 protein species. Moreover, we identified 10 and 15 differentially expressed proteins after 1h and 48h of Risedronate treatment, respectively. Among these, PARK7/DJ-1 protein levels were induced up to 3 times and this event was associated with the activation of the pro-survival Akt pathway that we propose as a novel player in the effect of N-BPs on osteocytes. Risedronate was also able to induce the expression and the secretion of the growth factor pro-granulin. In addition, protein prenylation inhibition appeared to be involved in the modulation of MLO-Y4 proteome by RIS in a protein-specific manner. In conclusion, these findings unveil novel functions targeted by N-BPs in osteocytes and could be useful to design novel pharmaceutical compounds.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jprot.2011.04.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Two Case Reports of Zoledronic Acid-Induced Acute Anterior Uveitis.
Cureus
October 2024
Endocrinology, Clínica Imbanaco, Cali, COL.
Zoledronic acid, or zoledronate, is a nitrogen-containing bisphosphonate widely used to treat osteoporosis and metastatic bone disease. It inhibits osteoclast function by binding to hydroxyapatite, reducing bone resorption and increasing bone mineral density. Despite its proven efficacy in increasing bone mineral density and reducing the incidence of fractures, adverse effects have been documented, including ocular side effects such as acute anterior uveitis.
View Article and Find Full Text PDFPeptides as modulators of FPPS enzyme: A multifaceted evaluation from the design to the mechanism of action.
Eur J Med Chem
December 2024
Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano, 49, 80131, Naples, Italy. Electronic address:
Article Synopsis
- Bone diseases result from an imbalance in bone remodeling due to increased activity of osteoclasts and decreased activity of osteoblasts, and the mevalonate pathway (MVA) is essential for maintaining this equilibrium through the action of the enzyme FPPS.
- FDA-approved nitrogen-containing bisphosphonates (N-BPs) target FPPS, highlighting its importance in treating bone-related diseases, while recent research focuses on developing new FPPS inhibitors using a combination of computational modeling, biochemical assays, and biophysical techniques.
- The study demonstrates that newly designed peptides and phosphopeptides effectively inhibit FPPS, showcasing potential as anti-cancer agents by impacting the MVA pathway in murine colorectal cancer cells.
Nitrogen-containing bisphosphonate induces enhancement of OPG expression and inhibition of RANKL expression via inhibition of farnesyl pyrophosphate synthase to inhibit the osteogenic differentiation and calcification in vascular smooth muscle cells.
BMC Cardiovasc Disord
September 2024
Department of Nephrology, First Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu, China.
Background: Nitrogen-containing bisphosphonate(N-BP)had been found to inhibit the osteogenic differentiation and calcification in vascular smooth muscle cells (VSMCs), but the mechanism is not clear. We intend to verify that N-BP induces enhancement of OPG expression and inhibition of RANKL expression via inhibition of farnesyl pyrophosphate synthase(FPPS) to inhibit the osteogenic differentiation and calcification in VSMCs.
Methods: β-glycerophosphate (β-GP) was used to induce the osteogenic differentiation and calcification in VSMCs.
Alendronate for Effective Treatment of Male Osteoporosis : An Insight.
Curr Pharm Des
September 2024
Department of Human and Clinical Anatomy, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.
Osteoporosis is a major global health problem. The increase in the incidence of osteoporosis in the elderly poses a challenge to treat and also results in an economic burden for the nation. Osteoporosis has been given more importance in females, and there is an urgent need to address this disease in males.
View Article and Find Full Text PDFDevelopment and Characterization of a Peptide-Bisphosphonate Nanoparticle for the Treatment of Breast Cancer.
Mol Pharm
October 2024
School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, BT9 7BL Northern Ireland, U.K.
In women, breast cancer (BC) is the most common cancer, and despite advancements in diagnosis and treatment, 20-30% of early stage BC patients develop metastatic disease. Metastatic BC is deemed an incurable disease, which accounts for 90% of BC related deaths, with only 26% of metastatic patients reaching a 5 year survival rate. Therefore, there is an unmet need for the prevention or treatment of metastasis in early stage breast cancer patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!